Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

Veeva Vault MedComms

Identity

• Founded: Veeva Systems founded 2007; Vault MedComms announced 2011. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-medcomms/]
• HQ: 4280 Hacienda Drive, Pleasanton, CA 94588 [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• Legal entity: Veeva Systems Inc. (NYSE: VEEV) [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• Funding: Public company (NYSE: VEEV). FY2025 revenue $2.75B; FY2026 revenue $3.20B. Market cap ~$35B as of research date. No venture funding outstanding. [THIRD-PARTY - https://stockanalysis.com/stocks/veev/financials/]
• Headcount: ~7,000 (estimated from public filings; not disclosed on product pages) [UNKNOWN - exact figure not published on vendor-accessible surfaces as of research date]
• Recent news (last 12 months):
• 2025 - Veeva announced Falcon, an agentic platform delivering AI labor for drug development workflows across the Vault platform. [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• 2025 - Teva committed to Veeva Vault CRM for worldwide implementation. [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• 2025 - Veeva acquired Ostro, a brand engagement platform for life sciences, adding HCP and patient engagement capabilities to the commercial cloud. [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• 2025 - Veeva announced eSource application to eliminate paper in clinical trial data collection. [VENDOR-CLAIMED - https://www.veeva.com/press-releases/]
• 2025 - Vault AI agents for PromoMats and Vault CRM went into general availability on the Vault Platform, with Anthropic and Amazon models via Amazon Bedrock as the underlying inference infrastructure. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-ai/]
• Archetype: Purpose-built Medical Affairs content lifecycle management platform running on the regulated Vault cloud. Veeva Vault MedComms handles the full lifecycle of medical content - from scientific statement creation and reference library management through multi-channel distribution to HCPs via CRM, Approved Email, and the Medical Portal. It is the Medical Affairs complement to PromoMats on the commercial side, and the two products share the same Vault Platform compliance and validation infrastructure. Primary buyers are Medical Affairs, Medical Information, and Publication teams at mid-to-large biopharma companies.

Total score: 85 / 100

• Stage fit:
• Foundation (<40 readiness): no - Enterprise-only; no self-serve trial. Minimum viable deployment requires Medical Affairs infrastructure that Foundation-stage companies rarely have.
• Pilot (40-59): conditional - Possible for companies that already have Vault CRM or PromoMats and can co-deploy MedComms on existing Vault infrastructure; standalone pilots are rare and procurement-heavy.
• Scale (60-79): yes - Strong fit. The product's design center is multi-brand, multi-geography, multi-channel Medical Affairs operations at scale.
• Optimization (80+): yes - Strongest fit. Named customers include Moderna, Merck, Biogen, Boehringer Ingelheim, Novo Nordisk, Roche, AstraZeneca. Reference architecture is enterprise pharma with full Vault integration stack.
• One-line verdict: The category standard for regulated Medical Affairs content management in large pharma - deep 21 CFR Part 11 / GxP compliance posture and tight Vault CRM integration are its primary moat, with pricing opacity and complex implementation as the consistent trade-off.

Headline numbers

Dimension scores

Pricing detail

Veeva does not publish a pricing page for Vault MedComms. Pricing is enterprise-negotiated and not available in the public domain. [UNKNOWN]

Key structural notes from available information: - No self-serve or trial tier. Access requires an enterprise contract. - Platform pricing model: Veeva typically bundles Vault applications at the platform level; MedComms is not sold as a standalone point solution in most procurement patterns. - Co-deployment economics: Companies already on Vault CRM or PromoMats typically pay a lower marginal cost to add MedComms vs. a greenfield deployment. First-time Vault deployments carry implementation and validation costs that are not disclosed publicly. - Implementation fees: IQ/OQ validation services under GxP are a material line item; Veeva partners with certified service providers for these.

Integrations

Source: https://www.veeva.com/products/vault-medcomms/

The integrates_with column for this vendor in D1 lists: veeva-vault-crm, veeva-vault-promomats.

• Veeva Vault CRM: Native bidirectional integration. MedComms content is automatically distributed to field-facing teams via CRM-linked CLM (Closed Loop Marketing) and Approved Email applications. Medical Affairs teams can surface approved scientific content directly to MSLs and Medical Science Liaisons through the CRM without leaving the Vault ecosystem. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-medcomms/]
• Veeva Vault PromoMats: Shared Vault Platform infrastructure means content, workflows, and reference libraries can be accessed across MedComms and PromoMats without re-implementation. MLR review workflows can be coordinated across both applications. Claims management and content reuse features in PromoMats are available as a complement to MedComms' scientific content governance. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-medcomms/]

Editorial assessment

Veeva Vault MedComms is the category-defining Medical Affairs content lifecycle management platform for large pharma. No other vendor has assembled a comparable combination of depth in regulated content workflows (scientific statements, reference libraries, MLR review), GxP-grade compliance infrastructure (ISO 27001, SOC 2 Type II, Diligent Pharma VQA covering 21 CFR Part 11), and native integration into the same CRM and promotional content platform that most top-20 biopharma companies already run. The 100+ customer base - which reads like the top-20 global biopharma roster with Moderna, Merck, Biogen, Roche, Novo Nordisk, Gilead, and AstraZeneca represented - is not the result of aggressive sales but of the Medical Affairs function following the commercial and regulatory functions onto Vault. That co-deployment pattern is the core moat: MedComms is most compelling when PromoMats and Vault CRM are already in place.

The gaps are structural, not incidental. Veeva does not publish pricing for MedComms on any customer-accessible surface, and implementation timelines at named enterprise accounts suggest multi-quarter deployments even for co-deployments with existing Vault products. The GxP validation requirements (IQ/OQ on every release, audit trails, e-signature configuration) add overhead that non-regulated SaaS competitors do not carry - that overhead is why the compliance posture scores 4/4, and why the time-to-value scores 2/4. The AI feature story for MedComms specifically (as opposed to PromoMats or the Falcon platform) is not publicly enumerated on the product page; buyers should confirm the MedComms-specific AI roadmap during procurement. The underlying inference infrastructure uses Anthropic and Amazon models via Amazon Bedrock, which is public, but model-specific task performance in regulated Medical Affairs content workflows is not benchmarked on any public surface.

For buyers outside the top-tier enterprise segment - mid-size specialty pharma, biotech pre-commercial, or any company evaluating its first Medical Affairs content system - the Veeva buy decision is a strategic commitment to the Vault ecosystem, not a point-solution evaluation. Buyers with existing Veeva footprints should model MedComms as a platform extension; buyers without an existing Veeva relationship should expect a longer procurement and implementation cycle and should validate whether the compliance requirements and integration depth justify the cost relative to lighter-weight alternatives.

Best for

• Stage: Scale (60-79) and Optimization (80+). Conditional for Pilot if existing Vault infrastructure is in place.
• Company profile: Mid-to-large biopharma ($250M+ revenue) with active Medical Affairs, MSL, and Medical Information functions; companies with existing Veeva Vault CRM or PromoMats deployments.
• Industry fit: Strong for global pharma, large biotech, specialty pharma. Moderate for medical devices (MedComms is pharma-centric; device Medical Affairs teams use different regulatory frameworks). Not a fit for pre-commercial biotech without an existing Vault relationship.
• Sales motion: Enterprise sales-led; multi-quarter procurement. Co-deployment alongside existing Vault products is the standard route. Independent evaluation is uncommon.
• Annual tooling budget: $500K+ annually at enterprise scale; implementation and validation costs are material additional items. [UNKNOWN - exact range not publicly disclosed]
• Skip if: (a) No existing Veeva Vault relationship and budget/timeline does not support a full platform deployment; (b) Company needs transparent, published pricing before procurement can start; (c) Compliance requirements do not include GxP or 21 CFR Part 11 (lighter-weight alternatives carry lower overhead); (d) Medical Affairs team is fewer than 5-10 people and does not yet need multi-geography content governance; (e) Fast time-to-value (under 6 months) is a procurement criterion.

Right-of-reply

Veeva received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Veeva was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Veeva was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

1. Headcount. Current employee count for Veeva Systems Inc. is not disclosed on product or investor pages accessible without authentication.
2. MedComms-specific AI roadmap. The Vault AI product page confirms Anthropic + Amazon models via Bedrock for the platform and names PromoMats and Vault CRM agents specifically; the MedComms agent roadmap is not enumerated. What MedComms-specific agents are GA or in beta?
3. HIPAA coverage. The public trust page (https://www.veeva.com/trust/) lists ISO 27001, ISO 27018, SOC 2 Type II, ISO 9001, and HDS, but does not explicitly name HIPAA. Does Veeva execute BAAs for MedComms deployments? Under what conditions?
4. Pricing structure. Is MedComms priced per user, per application, or as part of a Vault Commercial/Medical platform bundle? Is there a published starting price or benchmark range?
5. Implementation timeline. What is the median implementation timeline from contract to first production use for a greenfield MedComms deployment? For a co-deployment with existing PromoMats?
6. 21 CFR Part 11 explicit statement. The Diligent Pharma VQA covers "Computer Systems / 21 CFR Part 11 Compliance" as an audit scope item. Does Veeva publish a specific 21 CFR Part 11 compliance statement or IQ/OQ documentation package for MedComms customers?
7. SOC 2 Type II report. The trust page confirms the report exists. Where do customers request access to the full SOC 2 Type II report for procurement review?

Sources

Veeva first-party: - https://www.veeva.com/ - https://www.veeva.com/products/vault-medcomms/ - https://www.veeva.com/products/vault-platform/ - https://www.veeva.com/products/vault-ai/ - https://www.veeva.com/trust/ - https://www.veeva.com/press-releases/

Third-party financial / compliance: - https://stockanalysis.com/stocks/veev/financials/ - https://www.diligentpharma.com/veeva-vqa-report/ - https://rx-360.org/licenseanauditreport/

Note on research limitations: Most Veeva product subpages below the top-level product URL are authenticated or redirect; compliance certification details were sourced from the public trust page (https://www.veeva.com/trust/) and the Diligent Pharma VQA scope description. Buyers requiring the full SOC 2 Type II report or GxP qualification documentation should request these directly from their Veeva account team.